Unicycive Therapeutics, Inc. (NASDAQ:UNCY – Get Rating) was the recipient of a large increase in short interest in the month of December. As of December 30th, there was short interest totalling 259,000 shares, an increase of 284.3% from the December 15th total of 67,400 shares. Approximately 2.9% of the company's shares are sold short. Based on an average trading volume of 243,700 shares, the days-to-cover ratio is currently 1.1 days.
Unicycive Therapeutics Price Performance
Shares of UNCY traded down $0.00 during trading hours on Thursday, hitting $0.53. 62,326 shares of the stock were exchanged, compared to its average volume of 211,827. The firm has a market capitalization of $7.98 million, a P/E ratio of -0.52 and a beta of 1.35. The business has a 50-day moving average of $0.64 and a 200-day moving average of $0.69. Unicycive Therapeutics has a fifty-two week low of $0.40 and a fifty-two week high of $2.08.
Get
Unicycive Therapeutics alerts:
Unicycive Therapeutics (NASDAQ:UNCY – Get Rating) last posted its quarterly earnings results on Monday, November 14th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.02). The business had revenue of $0.95 million for the quarter. As a group, analysts forecast that Unicycive Therapeutics will post -1.13 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Unicycive Therapeutics
An institutional investor recently raised its position in Unicycive Therapeutics stock. Nantahala Capital Management LLC boosted its stake in Unicycive Therapeutics, Inc. (NASDAQ:UNCY – Get Rating) by 13.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 729,680 shares of the company's stock after purchasing an additional 89,047 shares during the quarter. Nantahala Capital Management LLC owned about 4.86% of Unicycive Therapeutics worth $606,000 as of its most recent SEC filing. 6.43% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Separately, HC Wainwright decreased their price target on shares of Unicycive Therapeutics from $9.00 to $8.00 and set a "buy" rating for the company in a research report on Monday, November 28th.
Unicycive Therapeutics Company Profile
(Get Rating)
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
See Also
- Get a free copy of the StockNews.com research report on Unicycive Therapeutics (UNCY)
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
- More Than One Reason To Buy Fastenal, Quickly
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
